nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—Chest pain—Fluorouracil—pancreatic cancer	0.00102	0.00124	CcSEcCtD
Brimonidine—Myalgia—Fluorouracil—pancreatic cancer	0.00102	0.00124	CcSEcCtD
Brimonidine—Infection—Irinotecan—pancreatic cancer	0.00101	0.00123	CcSEcCtD
Brimonidine—Pruritus—Erlotinib—pancreatic cancer	0.00101	0.00123	CcSEcCtD
Brimonidine—Discomfort—Fluorouracil—pancreatic cancer	0.00101	0.00123	CcSEcCtD
Brimonidine—Shock—Irinotecan—pancreatic cancer	0.001	0.00122	CcSEcCtD
Brimonidine—Nervous system disorder—Irinotecan—pancreatic cancer	0.001	0.00122	CcSEcCtD
Brimonidine—Rhinitis—Docetaxel—pancreatic cancer	0.000995	0.00121	CcSEcCtD
Brimonidine—Oedema—Gemcitabine—pancreatic cancer	0.000994	0.00121	CcSEcCtD
Brimonidine—Eye pain—Doxorubicin—pancreatic cancer	0.000992	0.00121	CcSEcCtD
Brimonidine—Lethargy—Epirubicin—pancreatic cancer	0.000988	0.0012	CcSEcCtD
Brimonidine—Infection—Gemcitabine—pancreatic cancer	0.000987	0.0012	CcSEcCtD
Brimonidine—Pharyngitis—Docetaxel—pancreatic cancer	0.000985	0.0012	CcSEcCtD
Brimonidine—Oedema—Fluorouracil—pancreatic cancer	0.000977	0.00119	CcSEcCtD
Brimonidine—Nervous system disorder—Gemcitabine—pancreatic cancer	0.000974	0.00119	CcSEcCtD
Brimonidine—Infection—Fluorouracil—pancreatic cancer	0.000971	0.00118	CcSEcCtD
Brimonidine—Osteoarthritis—Epirubicin—pancreatic cancer	0.000968	0.00118	CcSEcCtD
Brimonidine—Skin disorder—Gemcitabine—pancreatic cancer	0.000965	0.00118	CcSEcCtD
Brimonidine—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000958	0.00117	CcSEcCtD
Brimonidine—Visual impairment—Docetaxel—pancreatic cancer	0.000957	0.00117	CcSEcCtD
Brimonidine—Dizziness—Tamoxifen—pancreatic cancer	0.000956	0.00117	CcSEcCtD
Brimonidine—Tachycardia—Fluorouracil—pancreatic cancer	0.000954	0.00116	CcSEcCtD
Brimonidine—Hypotension—Irinotecan—pancreatic cancer	0.000953	0.00116	CcSEcCtD
Brimonidine—Dizziness—Erlotinib—pancreatic cancer	0.000946	0.00115	CcSEcCtD
Brimonidine—Face oedema—Epirubicin—pancreatic cancer	0.000934	0.00114	CcSEcCtD
Brimonidine—Hypotension—Gemcitabine—pancreatic cancer	0.000929	0.00113	CcSEcCtD
Brimonidine—Eye disorder—Docetaxel—pancreatic cancer	0.000928	0.00113	CcSEcCtD
Brimonidine—Insomnia—Irinotecan—pancreatic cancer	0.000923	0.00112	CcSEcCtD
Brimonidine—Cardiac disorder—Docetaxel—pancreatic cancer	0.000921	0.00112	CcSEcCtD
Brimonidine—Flushing—Docetaxel—pancreatic cancer	0.000921	0.00112	CcSEcCtD
Brimonidine—Paraesthesia—Irinotecan—pancreatic cancer	0.000916	0.00112	CcSEcCtD
Brimonidine—Lethargy—Doxorubicin—pancreatic cancer	0.000914	0.00111	CcSEcCtD
Brimonidine—Hypotension—Fluorouracil—pancreatic cancer	0.000913	0.00111	CcSEcCtD
Brimonidine—Hypersensitivity—Sunitinib—pancreatic cancer	0.000912	0.00111	CcSEcCtD
Brimonidine—Rash—Tamoxifen—pancreatic cancer	0.000912	0.00111	CcSEcCtD
Brimonidine—Dermatitis—Tamoxifen—pancreatic cancer	0.000911	0.00111	CcSEcCtD
Brimonidine—Dyspnoea—Irinotecan—pancreatic cancer	0.000909	0.00111	CcSEcCtD
Brimonidine—Somnolence—Irinotecan—pancreatic cancer	0.000907	0.00111	CcSEcCtD
Brimonidine—Headache—Tamoxifen—pancreatic cancer	0.000906	0.0011	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000905	0.0011	CcSEcCtD
Brimonidine—Rash—Erlotinib—pancreatic cancer	0.000902	0.0011	CcSEcCtD
Brimonidine—Dermatitis—Erlotinib—pancreatic cancer	0.000901	0.0011	CcSEcCtD
Brimonidine—Angiopathy—Docetaxel—pancreatic cancer	0.000901	0.0011	CcSEcCtD
Brimonidine—Insomnia—Gemcitabine—pancreatic cancer	0.000899	0.0011	CcSEcCtD
Brimonidine—Dyspepsia—Irinotecan—pancreatic cancer	0.000898	0.00109	CcSEcCtD
Brimonidine—Immune system disorder—Docetaxel—pancreatic cancer	0.000897	0.00109	CcSEcCtD
Brimonidine—Headache—Erlotinib—pancreatic cancer	0.000896	0.00109	CcSEcCtD
Brimonidine—Osteoarthritis—Doxorubicin—pancreatic cancer	0.000895	0.00109	CcSEcCtD
Brimonidine—Mediastinal disorder—Docetaxel—pancreatic cancer	0.000895	0.00109	CcSEcCtD
Brimonidine—Paraesthesia—Gemcitabine—pancreatic cancer	0.000892	0.00109	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.00089	0.00108	CcSEcCtD
Brimonidine—Asthenia—Sunitinib—pancreatic cancer	0.000889	0.00108	CcSEcCtD
Brimonidine—Dry skin—Epirubicin—pancreatic cancer	0.000887	0.00108	CcSEcCtD
Brimonidine—Arrhythmia—Docetaxel—pancreatic cancer	0.000887	0.00108	CcSEcCtD
Brimonidine—Dyspnoea—Gemcitabine—pancreatic cancer	0.000886	0.00108	CcSEcCtD
Brimonidine—Insomnia—Fluorouracil—pancreatic cancer	0.000884	0.00108	CcSEcCtD
Brimonidine—Somnolence—Gemcitabine—pancreatic cancer	0.000883	0.00108	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000881	0.00107	CcSEcCtD
Brimonidine—Fatigue—Irinotecan—pancreatic cancer	0.000879	0.00107	CcSEcCtD
Brimonidine—Paraesthesia—Fluorouracil—pancreatic cancer	0.000877	0.00107	CcSEcCtD
Brimonidine—Pruritus—Sunitinib—pancreatic cancer	0.000876	0.00107	CcSEcCtD
Brimonidine—Pain—Irinotecan—pancreatic cancer	0.000872	0.00106	CcSEcCtD
Brimonidine—Dyspnoea—Fluorouracil—pancreatic cancer	0.000871	0.00106	CcSEcCtD
Brimonidine—Mental disorder—Docetaxel—pancreatic cancer	0.00087	0.00106	CcSEcCtD
Brimonidine—Somnolence—Fluorouracil—pancreatic cancer	0.000869	0.00106	CcSEcCtD
Brimonidine—Nasopharyngitis—Epirubicin—pancreatic cancer	0.000865	0.00105	CcSEcCtD
Brimonidine—Face oedema—Doxorubicin—pancreatic cancer	0.000864	0.00105	CcSEcCtD
Brimonidine—Erythema—Docetaxel—pancreatic cancer	0.000864	0.00105	CcSEcCtD
Brimonidine—Dyspepsia—Fluorouracil—pancreatic cancer	0.00086	0.00105	CcSEcCtD
Brimonidine—Nausea—Tamoxifen—pancreatic cancer	0.000859	0.00105	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000858	0.00105	CcSEcCtD
Brimonidine—Fatigue—Gemcitabine—pancreatic cancer	0.000857	0.00104	CcSEcCtD
Brimonidine—Pain—Gemcitabine—pancreatic cancer	0.00085	0.00104	CcSEcCtD
Brimonidine—Nausea—Erlotinib—pancreatic cancer	0.00085	0.00104	CcSEcCtD
Brimonidine—Dysgeusia—Docetaxel—pancreatic cancer	0.000846	0.00103	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000843	0.00103	CcSEcCtD
Brimonidine—Influenza—Epirubicin—pancreatic cancer	0.000836	0.00102	CcSEcCtD
Brimonidine—Pain—Fluorouracil—pancreatic cancer	0.000835	0.00102	CcSEcCtD
Brimonidine—Dry skin—Doxorubicin—pancreatic cancer	0.000821	0.001	CcSEcCtD
Brimonidine—Dizziness—Sunitinib—pancreatic cancer	0.000819	0.000998	CcSEcCtD
Brimonidine—Bronchitis—Epirubicin—pancreatic cancer	0.000804	0.00098	CcSEcCtD
Brimonidine—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.000801	0.000976	CcSEcCtD
Brimonidine—Rash—Sunitinib—pancreatic cancer	0.000781	0.000951	CcSEcCtD
Brimonidine—Dermatitis—Sunitinib—pancreatic cancer	0.00078	0.000951	CcSEcCtD
Brimonidine—Headache—Sunitinib—pancreatic cancer	0.000776	0.000945	CcSEcCtD
Brimonidine—Syncope—Docetaxel—pancreatic cancer	0.000775	0.000944	CcSEcCtD
Brimonidine—Influenza—Doxorubicin—pancreatic cancer	0.000774	0.000943	CcSEcCtD
Brimonidine—Palpitations—Docetaxel—pancreatic cancer	0.000764	0.00093	CcSEcCtD
Brimonidine—Loss of consciousness—Docetaxel—pancreatic cancer	0.000759	0.000925	CcSEcCtD
Brimonidine—Cough—Docetaxel—pancreatic cancer	0.000754	0.000919	CcSEcCtD
Brimonidine—Hypersensitivity—Irinotecan—pancreatic cancer	0.000752	0.000916	CcSEcCtD
Brimonidine—Hypertension—Docetaxel—pancreatic cancer	0.000746	0.000909	CcSEcCtD
Brimonidine—Drowsiness—Epirubicin—pancreatic cancer	0.000746	0.000909	CcSEcCtD
Brimonidine—Bronchitis—Doxorubicin—pancreatic cancer	0.000744	0.000907	CcSEcCtD
Brimonidine—Chest pain—Docetaxel—pancreatic cancer	0.000736	0.000896	CcSEcCtD
Brimonidine—Myalgia—Docetaxel—pancreatic cancer	0.000736	0.000896	CcSEcCtD
Brimonidine—Arthralgia—Docetaxel—pancreatic cancer	0.000736	0.000896	CcSEcCtD
Brimonidine—Nausea—Sunitinib—pancreatic cancer	0.000736	0.000896	CcSEcCtD
Brimonidine—Asthenia—Irinotecan—pancreatic cancer	0.000732	0.000892	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000731	0.00089	CcSEcCtD
Brimonidine—Conjunctivitis—Epirubicin—pancreatic cancer	0.000725	0.000883	CcSEcCtD
Brimonidine—Hypersensitivity—Fluorouracil—pancreatic cancer	0.00072	0.000877	CcSEcCtD
Brimonidine—Dry mouth—Docetaxel—pancreatic cancer	0.000719	0.000877	CcSEcCtD
Brimonidine—Asthenia—Gemcitabine—pancreatic cancer	0.000713	0.000869	CcSEcCtD
Brimonidine—Oedema—Docetaxel—pancreatic cancer	0.000705	0.000859	CcSEcCtD
Brimonidine—Pruritus—Gemcitabine—pancreatic cancer	0.000703	0.000857	CcSEcCtD
Brimonidine—Infection—Docetaxel—pancreatic cancer	0.000701	0.000854	CcSEcCtD
Brimonidine—Sinusitis—Epirubicin—pancreatic cancer	0.0007	0.000853	CcSEcCtD
Brimonidine—Shock—Docetaxel—pancreatic cancer	0.000694	0.000845	CcSEcCtD
Brimonidine—Nervous system disorder—Docetaxel—pancreatic cancer	0.000692	0.000843	CcSEcCtD
Brimonidine—Pruritus—Fluorouracil—pancreatic cancer	0.000691	0.000842	CcSEcCtD
Brimonidine—Drowsiness—Doxorubicin—pancreatic cancer	0.00069	0.000841	CcSEcCtD
Brimonidine—Tachycardia—Docetaxel—pancreatic cancer	0.000688	0.000839	CcSEcCtD
Brimonidine—Skin disorder—Docetaxel—pancreatic cancer	0.000685	0.000835	CcSEcCtD
Brimonidine—Bradycardia—Epirubicin—pancreatic cancer	0.000682	0.00083	CcSEcCtD
Brimonidine—Dizziness—Irinotecan—pancreatic cancer	0.000675	0.000822	CcSEcCtD
Brimonidine—Rhinitis—Epirubicin—pancreatic cancer	0.000671	0.000818	CcSEcCtD
Brimonidine—Conjunctivitis—Doxorubicin—pancreatic cancer	0.000671	0.000817	CcSEcCtD
Brimonidine—Pharyngitis—Epirubicin—pancreatic cancer	0.000664	0.00081	CcSEcCtD
Brimonidine—Hypotension—Docetaxel—pancreatic cancer	0.000659	0.000803	CcSEcCtD
Brimonidine—Sinusitis—Doxorubicin—pancreatic cancer	0.000647	0.000789	CcSEcCtD
Brimonidine—Dizziness—Fluorouracil—pancreatic cancer	0.000646	0.000787	CcSEcCtD
Brimonidine—Visual impairment—Epirubicin—pancreatic cancer	0.000645	0.000786	CcSEcCtD
Brimonidine—Rash—Irinotecan—pancreatic cancer	0.000643	0.000784	CcSEcCtD
Brimonidine—Dermatitis—Irinotecan—pancreatic cancer	0.000643	0.000783	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000642	0.000783	CcSEcCtD
Brimonidine—Headache—Irinotecan—pancreatic cancer	0.000639	0.000779	CcSEcCtD
Brimonidine—Insomnia—Docetaxel—pancreatic cancer	0.000638	0.000777	CcSEcCtD
Brimonidine—Paraesthesia—Docetaxel—pancreatic cancer	0.000633	0.000772	CcSEcCtD
Brimonidine—Bradycardia—Doxorubicin—pancreatic cancer	0.000631	0.000768	CcSEcCtD
Brimonidine—Dyspnoea—Docetaxel—pancreatic cancer	0.000629	0.000766	CcSEcCtD
Brimonidine—Somnolence—Docetaxel—pancreatic cancer	0.000627	0.000764	CcSEcCtD
Brimonidine—Rash—Gemcitabine—pancreatic cancer	0.000627	0.000763	CcSEcCtD
Brimonidine—Dermatitis—Gemcitabine—pancreatic cancer	0.000626	0.000763	CcSEcCtD
Brimonidine—Eye disorder—Epirubicin—pancreatic cancer	0.000626	0.000762	CcSEcCtD
Brimonidine—Headache—Gemcitabine—pancreatic cancer	0.000622	0.000759	CcSEcCtD
Brimonidine—Flushing—Epirubicin—pancreatic cancer	0.000621	0.000757	CcSEcCtD
Brimonidine—Cardiac disorder—Epirubicin—pancreatic cancer	0.000621	0.000757	CcSEcCtD
Brimonidine—Rhinitis—Doxorubicin—pancreatic cancer	0.000621	0.000757	CcSEcCtD
Brimonidine—Dyspepsia—Docetaxel—pancreatic cancer	0.000621	0.000756	CcSEcCtD
Brimonidine—Rash—Fluorouracil—pancreatic cancer	0.000616	0.000751	CcSEcCtD
Brimonidine—Dermatitis—Fluorouracil—pancreatic cancer	0.000615	0.00075	CcSEcCtD
Brimonidine—Pharyngitis—Doxorubicin—pancreatic cancer	0.000615	0.000749	CcSEcCtD
Brimonidine—Headache—Fluorouracil—pancreatic cancer	0.000612	0.000746	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000609	0.000742	CcSEcCtD
Brimonidine—Fatigue—Docetaxel—pancreatic cancer	0.000608	0.000741	CcSEcCtD
Brimonidine—Angiopathy—Epirubicin—pancreatic cancer	0.000607	0.00074	CcSEcCtD
Brimonidine—Nausea—Irinotecan—pancreatic cancer	0.000606	0.000738	CcSEcCtD
Brimonidine—Immune system disorder—Epirubicin—pancreatic cancer	0.000605	0.000737	CcSEcCtD
Brimonidine—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000603	0.000735	CcSEcCtD
Brimonidine—Pain—Docetaxel—pancreatic cancer	0.000603	0.000735	CcSEcCtD
Brimonidine—Arrhythmia—Epirubicin—pancreatic cancer	0.000598	0.000729	CcSEcCtD
Brimonidine—Visual impairment—Doxorubicin—pancreatic cancer	0.000597	0.000727	CcSEcCtD
Brimonidine—Nausea—Gemcitabine—pancreatic cancer	0.00059	0.000719	CcSEcCtD
Brimonidine—Mental disorder—Epirubicin—pancreatic cancer	0.000587	0.000715	CcSEcCtD
Brimonidine—Erythema—Epirubicin—pancreatic cancer	0.000583	0.00071	CcSEcCtD
Brimonidine—Nausea—Fluorouracil—pancreatic cancer	0.00058	0.000707	CcSEcCtD
Brimonidine—Eye disorder—Doxorubicin—pancreatic cancer	0.000579	0.000705	CcSEcCtD
Brimonidine—Flushing—Doxorubicin—pancreatic cancer	0.000575	0.000701	CcSEcCtD
Brimonidine—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000575	0.000701	CcSEcCtD
Brimonidine—Dysgeusia—Epirubicin—pancreatic cancer	0.000571	0.000695	CcSEcCtD
Brimonidine—Angiopathy—Doxorubicin—pancreatic cancer	0.000562	0.000685	CcSEcCtD
Brimonidine—Immune system disorder—Doxorubicin—pancreatic cancer	0.00056	0.000682	CcSEcCtD
Brimonidine—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000558	0.00068	CcSEcCtD
Brimonidine—Arrhythmia—Doxorubicin—pancreatic cancer	0.000553	0.000674	CcSEcCtD
Brimonidine—Vision blurred—Epirubicin—pancreatic cancer	0.000549	0.000669	CcSEcCtD
Brimonidine—Mental disorder—Doxorubicin—pancreatic cancer	0.000543	0.000661	CcSEcCtD
Brimonidine—Erythema—Doxorubicin—pancreatic cancer	0.000539	0.000657	CcSEcCtD
Brimonidine—Dysgeusia—Doxorubicin—pancreatic cancer	0.000528	0.000643	CcSEcCtD
Brimonidine—Syncope—Epirubicin—pancreatic cancer	0.000523	0.000637	CcSEcCtD
Brimonidine—Hypersensitivity—Docetaxel—pancreatic cancer	0.00052	0.000633	CcSEcCtD
Brimonidine—Palpitations—Epirubicin—pancreatic cancer	0.000515	0.000628	CcSEcCtD
Brimonidine—Loss of consciousness—Epirubicin—pancreatic cancer	0.000512	0.000624	CcSEcCtD
Brimonidine—Cough—Epirubicin—pancreatic cancer	0.000509	0.00062	CcSEcCtD
Brimonidine—Vision blurred—Doxorubicin—pancreatic cancer	0.000508	0.000619	CcSEcCtD
Brimonidine—Asthenia—Docetaxel—pancreatic cancer	0.000506	0.000616	CcSEcCtD
Brimonidine—Hypertension—Epirubicin—pancreatic cancer	0.000503	0.000613	CcSEcCtD
Brimonidine—Pruritus—Docetaxel—pancreatic cancer	0.000499	0.000608	CcSEcCtD
Brimonidine—Arthralgia—Epirubicin—pancreatic cancer	0.000496	0.000605	CcSEcCtD
Brimonidine—Chest pain—Epirubicin—pancreatic cancer	0.000496	0.000605	CcSEcCtD
Brimonidine—Myalgia—Epirubicin—pancreatic cancer	0.000496	0.000605	CcSEcCtD
Brimonidine—Anxiety—Epirubicin—pancreatic cancer	0.000494	0.000602	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000493	0.0006	CcSEcCtD
Brimonidine—Discomfort—Epirubicin—pancreatic cancer	0.00049	0.000597	CcSEcCtD
Brimonidine—Dry mouth—Epirubicin—pancreatic cancer	0.000485	0.000591	CcSEcCtD
Brimonidine—Syncope—Doxorubicin—pancreatic cancer	0.000484	0.000589	CcSEcCtD
Brimonidine—Palpitations—Doxorubicin—pancreatic cancer	0.000477	0.000581	CcSEcCtD
Brimonidine—Oedema—Epirubicin—pancreatic cancer	0.000476	0.00058	CcSEcCtD
Brimonidine—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000474	0.000578	CcSEcCtD
Brimonidine—Infection—Epirubicin—pancreatic cancer	0.000473	0.000576	CcSEcCtD
Brimonidine—Cough—Doxorubicin—pancreatic cancer	0.000471	0.000573	CcSEcCtD
Brimonidine—Shock—Epirubicin—pancreatic cancer	0.000468	0.00057	CcSEcCtD
Brimonidine—Nervous system disorder—Epirubicin—pancreatic cancer	0.000466	0.000568	CcSEcCtD
Brimonidine—Dizziness—Docetaxel—pancreatic cancer	0.000466	0.000568	CcSEcCtD
Brimonidine—Hypertension—Doxorubicin—pancreatic cancer	0.000466	0.000567	CcSEcCtD
Brimonidine—Tachycardia—Epirubicin—pancreatic cancer	0.000464	0.000566	CcSEcCtD
Brimonidine—Skin disorder—Epirubicin—pancreatic cancer	0.000462	0.000563	CcSEcCtD
Brimonidine—Arthralgia—Doxorubicin—pancreatic cancer	0.000459	0.000559	CcSEcCtD
Brimonidine—Myalgia—Doxorubicin—pancreatic cancer	0.000459	0.000559	CcSEcCtD
Brimonidine—Chest pain—Doxorubicin—pancreatic cancer	0.000459	0.000559	CcSEcCtD
Brimonidine—Anxiety—Doxorubicin—pancreatic cancer	0.000457	0.000557	CcSEcCtD
Brimonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	0.000456	0.000556	CcSEcCtD
Brimonidine—Discomfort—Doxorubicin—pancreatic cancer	0.000454	0.000553	CcSEcCtD
Brimonidine—Dry mouth—Doxorubicin—pancreatic cancer	0.000449	0.000547	CcSEcCtD
Brimonidine—Rash—Docetaxel—pancreatic cancer	0.000445	0.000542	CcSEcCtD
Brimonidine—Hypotension—Epirubicin—pancreatic cancer	0.000444	0.000542	CcSEcCtD
Brimonidine—Dermatitis—Docetaxel—pancreatic cancer	0.000444	0.000541	CcSEcCtD
Brimonidine—Headache—Docetaxel—pancreatic cancer	0.000442	0.000538	CcSEcCtD
Brimonidine—Oedema—Doxorubicin—pancreatic cancer	0.00044	0.000536	CcSEcCtD
Brimonidine—Infection—Doxorubicin—pancreatic cancer	0.000437	0.000533	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000433	0.000528	CcSEcCtD
Brimonidine—Shock—Doxorubicin—pancreatic cancer	0.000433	0.000528	CcSEcCtD
Brimonidine—Nervous system disorder—Doxorubicin—pancreatic cancer	0.000432	0.000526	CcSEcCtD
Brimonidine—Insomnia—Epirubicin—pancreatic cancer	0.00043	0.000524	CcSEcCtD
Brimonidine—Tachycardia—Doxorubicin—pancreatic cancer	0.00043	0.000523	CcSEcCtD
Brimonidine—Skin disorder—Doxorubicin—pancreatic cancer	0.000427	0.000521	CcSEcCtD
Brimonidine—Paraesthesia—Epirubicin—pancreatic cancer	0.000427	0.00052	CcSEcCtD
Brimonidine—Dyspnoea—Epirubicin—pancreatic cancer	0.000424	0.000517	CcSEcCtD
Brimonidine—Somnolence—Epirubicin—pancreatic cancer	0.000423	0.000515	CcSEcCtD
Brimonidine—Nausea—Docetaxel—pancreatic cancer	0.000419	0.00051	CcSEcCtD
Brimonidine—Dyspepsia—Epirubicin—pancreatic cancer	0.000419	0.00051	CcSEcCtD
Brimonidine—Hypotension—Doxorubicin—pancreatic cancer	0.000411	0.000501	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000411	0.0005	CcSEcCtD
Brimonidine—Fatigue—Epirubicin—pancreatic cancer	0.00041	0.0005	CcSEcCtD
Brimonidine—Pain—Epirubicin—pancreatic cancer	0.000407	0.000496	CcSEcCtD
Brimonidine—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000401	0.000489	CcSEcCtD
Brimonidine—Insomnia—Doxorubicin—pancreatic cancer	0.000398	0.000485	CcSEcCtD
Brimonidine—Paraesthesia—Doxorubicin—pancreatic cancer	0.000395	0.000482	CcSEcCtD
Brimonidine—Dyspnoea—Doxorubicin—pancreatic cancer	0.000392	0.000478	CcSEcCtD
Brimonidine—Somnolence—Doxorubicin—pancreatic cancer	0.000391	0.000477	CcSEcCtD
Brimonidine—Dyspepsia—Doxorubicin—pancreatic cancer	0.000387	0.000472	CcSEcCtD
Brimonidine—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.00038	0.000463	CcSEcCtD
Brimonidine—Fatigue—Doxorubicin—pancreatic cancer	0.000379	0.000462	CcSEcCtD
Brimonidine—Pain—Doxorubicin—pancreatic cancer	0.000376	0.000459	CcSEcCtD
Brimonidine—Hypersensitivity—Epirubicin—pancreatic cancer	0.00035	0.000427	CcSEcCtD
Brimonidine—Asthenia—Epirubicin—pancreatic cancer	0.000341	0.000416	CcSEcCtD
Brimonidine—Pruritus—Epirubicin—pancreatic cancer	0.000337	0.00041	CcSEcCtD
Brimonidine—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000324	0.000395	CcSEcCtD
Brimonidine—Asthenia—Doxorubicin—pancreatic cancer	0.000316	0.000385	CcSEcCtD
Brimonidine—Dizziness—Epirubicin—pancreatic cancer	0.000315	0.000383	CcSEcCtD
Brimonidine—Pruritus—Doxorubicin—pancreatic cancer	0.000311	0.000379	CcSEcCtD
Brimonidine—Rash—Epirubicin—pancreatic cancer	0.0003	0.000365	CcSEcCtD
Brimonidine—Dermatitis—Epirubicin—pancreatic cancer	0.0003	0.000365	CcSEcCtD
Brimonidine—Headache—Epirubicin—pancreatic cancer	0.000298	0.000363	CcSEcCtD
Brimonidine—Dizziness—Doxorubicin—pancreatic cancer	0.000291	0.000355	CcSEcCtD
Brimonidine—Nausea—Epirubicin—pancreatic cancer	0.000283	0.000344	CcSEcCtD
Brimonidine—Rash—Doxorubicin—pancreatic cancer	0.000277	0.000338	CcSEcCtD
Brimonidine—Dermatitis—Doxorubicin—pancreatic cancer	0.000277	0.000338	CcSEcCtD
Brimonidine—Headache—Doxorubicin—pancreatic cancer	0.000276	0.000336	CcSEcCtD
Brimonidine—Nausea—Doxorubicin—pancreatic cancer	0.000261	0.000319	CcSEcCtD
Brimonidine—ADRA2C—Signaling Pathways—IAPP—pancreatic cancer	0.000106	0.00059	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SCT—pancreatic cancer	0.000104	0.000582	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HEY1—pancreatic cancer	0.000104	0.000582	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CD—pancreatic cancer	0.000104	0.000577	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CD44—pancreatic cancer	0.000103	0.000576	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CB—pancreatic cancer	0.000103	0.000576	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PTGS2—pancreatic cancer	0.000102	0.000571	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTHLH—pancreatic cancer	0.000102	0.000567	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTCH1—pancreatic cancer	0.000102	0.000567	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCK—pancreatic cancer	9.96e-05	0.000555	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SST—pancreatic cancer	9.95e-05	0.000555	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—GCG—pancreatic cancer	9.91e-05	0.000552	CbGpPWpGaD
Brimonidine—AOX1—Disease—SRC—pancreatic cancer	9.89e-05	0.000551	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.81e-05	0.000547	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—JAG1—pancreatic cancer	9.74e-05	0.000543	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CNR2—pancreatic cancer	9.71e-05	0.000541	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GLP1R—pancreatic cancer	9.71e-05	0.000541	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—CXCL8—pancreatic cancer	9.7e-05	0.000541	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH3—pancreatic cancer	9.69e-05	0.000541	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCKAR—pancreatic cancer	9.55e-05	0.000532	CbGpPWpGaD
Brimonidine—AOX1—Disease—STAT3—pancreatic cancer	9.53e-05	0.000532	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—SRC—pancreatic cancer	9.53e-05	0.000532	CbGpPWpGaD
Brimonidine—AOX1—Disease—NRAS—pancreatic cancer	9.51e-05	0.00053	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—STK11—pancreatic cancer	9.31e-05	0.000519	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SST—pancreatic cancer	9.29e-05	0.000518	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—VEGFA—pancreatic cancer	9.29e-05	0.000518	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JAG2—pancreatic cancer	9.26e-05	0.000516	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CNR1—pancreatic cancer	9.18e-05	0.000512	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—NRAS—pancreatic cancer	9.17e-05	0.000511	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CG—pancreatic cancer	9.17e-05	0.000511	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MEN1—pancreatic cancer	9.13e-05	0.000509	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—JAG1—pancreatic cancer	9.09e-05	0.000507	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH3—pancreatic cancer	9.06e-05	0.000505	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CB—pancreatic cancer	9.03e-05	0.000503	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PTEN—pancreatic cancer	8.93e-05	0.000498	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CG—pancreatic cancer	8.91e-05	0.000497	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—SRC—pancreatic cancer	8.91e-05	0.000497	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GCG—pancreatic cancer	8.87e-05	0.000494	CbGpPWpGaD
Brimonidine—AOX1—Disease—MYC—pancreatic cancer	8.86e-05	0.000494	CbGpPWpGaD
Brimonidine—AOX1—Disease—TGFB1—pancreatic cancer	8.84e-05	0.000493	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	8.72e-05	0.000486	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SHH—pancreatic cancer	8.71e-05	0.000485	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—VEGFA—pancreatic cancer	8.67e-05	0.000484	CbGpPWpGaD
Brimonidine—AOX1—Disease—EGFR—pancreatic cancer	8.66e-05	0.000483	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH4—pancreatic cancer	8.65e-05	0.000482	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.63e-05	0.000481	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—IAPP—pancreatic cancer	8.6e-05	0.000479	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CNR1—pancreatic cancer	8.58e-05	0.000478	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—NRAS—pancreatic cancer	8.57e-05	0.000478	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TGFB1—pancreatic cancer	8.52e-05	0.000475	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AGTR1—pancreatic cancer	8.46e-05	0.000472	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CD44—pancreatic cancer	8.39e-05	0.000468	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STK11—pancreatic cancer	8.34e-05	0.000465	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CG—pancreatic cancer	8.32e-05	0.000464	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GCG—pancreatic cancer	8.28e-05	0.000462	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTHLH—pancreatic cancer	8.25e-05	0.00046	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTCH1—pancreatic cancer	8.25e-05	0.00046	CbGpPWpGaD
Brimonidine—AOX1—Disease—KRAS—pancreatic cancer	8.19e-05	0.000456	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CD—pancreatic cancer	8.06e-05	0.000449	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—GCG—pancreatic cancer	8.05e-05	0.000449	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TYMS—pancreatic cancer	8.01e-05	0.000447	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TGFB1—pancreatic cancer	7.96e-05	0.000444	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AGTR1—pancreatic cancer	7.9e-05	0.000441	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—KRAS—pancreatic cancer	7.89e-05	0.00044	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CD—pancreatic cancer	7.83e-05	0.000437	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STK11—pancreatic cancer	7.79e-05	0.000434	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—STK11—pancreatic cancer	7.56e-05	0.000422	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SST—pancreatic cancer	7.55e-05	0.000421	CbGpPWpGaD
Brimonidine—AOX1—Disease—PIK3CA—pancreatic cancer	7.52e-05	0.000419	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.52e-05	0.000419	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CG—pancreatic cancer	7.44e-05	0.000415	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—JAG1—pancreatic cancer	7.39e-05	0.000412	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—KRAS—pancreatic cancer	7.37e-05	0.000411	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH3—pancreatic cancer	7.36e-05	0.00041	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CD—pancreatic cancer	7.32e-05	0.000408	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SMAD4—pancreatic cancer	7.3e-05	0.000407	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—PIK3CA—pancreatic cancer	7.25e-05	0.000404	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—SRC—pancreatic cancer	7.23e-05	0.000403	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—CXCL8—pancreatic cancer	7.22e-05	0.000403	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HES1—pancreatic cancer	7.13e-05	0.000398	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—VEGFA—pancreatic cancer	7.04e-05	0.000393	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CB—pancreatic cancer	7.02e-05	0.000392	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—TP53—pancreatic cancer	7.02e-05	0.000391	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CNR1—pancreatic cancer	6.97e-05	0.000388	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—NRAS—pancreatic cancer	6.96e-05	0.000388	CbGpPWpGaD
Brimonidine—AOX1—Disease—HRAS—pancreatic cancer	6.96e-05	0.000388	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CB—pancreatic cancer	6.83e-05	0.000381	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SMAD4—pancreatic cancer	6.82e-05	0.00038	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—PIK3CA—pancreatic cancer	6.77e-05	0.000378	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CG—pancreatic cancer	6.76e-05	0.000377	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—CXCL8—pancreatic cancer	6.75e-05	0.000376	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GCG—pancreatic cancer	6.73e-05	0.000375	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—HRAS—pancreatic cancer	6.71e-05	0.000374	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HES1—pancreatic cancer	6.66e-05	0.000371	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—CXCL8—pancreatic cancer	6.56e-05	0.000366	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—TP53—pancreatic cancer	6.55e-05	0.000365	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CD—pancreatic cancer	6.54e-05	0.000365	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—APOE—pancreatic cancer	6.52e-05	0.000363	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TYMS—pancreatic cancer	6.51e-05	0.000363	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TGFB1—pancreatic cancer	6.47e-05	0.000361	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AGTR1—pancreatic cancer	6.42e-05	0.000358	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CB—pancreatic cancer	6.38e-05	0.000356	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STK11—pancreatic cancer	6.33e-05	0.000353	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—PIK3CA—pancreatic cancer	6.3e-05	0.000351	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—HRAS—pancreatic cancer	6.27e-05	0.000349	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TERT—pancreatic cancer	6.25e-05	0.000348	CbGpPWpGaD
Brimonidine—AOX1—Disease—AKT1—pancreatic cancer	6.14e-05	0.000343	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—CXCL8—pancreatic cancer	6.13e-05	0.000342	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—KRAS—pancreatic cancer	5.99e-05	0.000334	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HIF1A—pancreatic cancer	5.97e-05	0.000333	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TSC2—pancreatic cancer	5.96e-05	0.000332	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CD—pancreatic cancer	5.94e-05	0.000331	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—AKT1—pancreatic cancer	5.92e-05	0.00033	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CG—pancreatic cancer	5.88e-05	0.000328	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TERT—pancreatic cancer	5.84e-05	0.000325	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—APOE—pancreatic cancer	5.83e-05	0.000325	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KDR—pancreatic cancer	5.71e-05	0.000319	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CB—pancreatic cancer	5.7e-05	0.000318	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PPARG—pancreatic cancer	5.68e-05	0.000316	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HIF1A—pancreatic cancer	5.58e-05	0.000311	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TSC2—pancreatic cancer	5.57e-05	0.00031	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SMAD4—pancreatic cancer	5.54e-05	0.000309	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—AKT1—pancreatic cancer	5.53e-05	0.000309	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—PIK3CA—pancreatic cancer	5.5e-05	0.000307	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—CXCL8—pancreatic cancer	5.48e-05	0.000306	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—APOE—pancreatic cancer	5.45e-05	0.000304	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NFKBIA—pancreatic cancer	5.43e-05	0.000303	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HES1—pancreatic cancer	5.41e-05	0.000302	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NOTCH1—pancreatic cancer	5.38e-05	0.0003	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KDR—pancreatic cancer	5.34e-05	0.000298	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—TP53—pancreatic cancer	5.32e-05	0.000297	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—APOE—pancreatic cancer	5.29e-05	0.000295	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CG—pancreatic cancer	5.26e-05	0.000294	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—NRAS—pancreatic cancer	5.26e-05	0.000294	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGF—pancreatic cancer	5.2e-05	0.00029	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CB—pancreatic cancer	5.18e-05	0.000289	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CD—pancreatic cancer	5.17e-05	0.000288	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—AKT1—pancreatic cancer	5.14e-05	0.000287	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—HRAS—pancreatic cancer	5.09e-05	0.000284	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NFKBIA—pancreatic cancer	5.08e-05	0.000283	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NOTCH1—pancreatic cancer	5.03e-05	0.00028	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—CXCL8—pancreatic cancer	4.98e-05	0.000278	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CG—pancreatic cancer	4.92e-05	0.000274	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—NRAS—pancreatic cancer	4.92e-05	0.000274	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGF—pancreatic cancer	4.86e-05	0.000271	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—EGFR—pancreatic cancer	4.8e-05	0.000267	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	4.78e-05	0.000266	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	4.74e-05	0.000264	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CD—pancreatic cancer	4.63e-05	0.000258	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PPARG—pancreatic cancer	4.61e-05	0.000257	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.58e-05	0.000256	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	4.53e-05	0.000253	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—KRAS—pancreatic cancer	4.53e-05	0.000253	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	4.52e-05	0.000252	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CB—pancreatic cancer	4.51e-05	0.000251	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—AKT1—pancreatic cancer	4.5e-05	0.000251	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—EGFR—pancreatic cancer	4.48e-05	0.00025	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTGS2—pancreatic cancer	4.46e-05	0.000249	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	4.43e-05	0.000247	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	4.34e-05	0.000242	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CD—pancreatic cancer	4.32e-05	0.000241	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.28e-05	0.000239	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—KRAS—pancreatic cancer	4.23e-05	0.000236	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	4.2e-05	0.000234	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—PIK3CA—pancreatic cancer	4.16e-05	0.000232	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	4.12e-05	0.00023	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	4.08e-05	0.000228	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CB—pancreatic cancer	4.03e-05	0.000225	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	3.99e-05	0.000223	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	3.99e-05	0.000223	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	3.95e-05	0.00022	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PTEN—pancreatic cancer	3.89e-05	0.000217	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—PIK3CA—pancreatic cancer	3.89e-05	0.000217	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	3.88e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	3.85e-05	0.000215	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	3.77e-05	0.00021	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	3.74e-05	0.000209	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	3.71e-05	0.000207	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	3.66e-05	0.000204	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	3.64e-05	0.000203	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTGS2—pancreatic cancer	3.63e-05	0.000202	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	3.62e-05	0.000202	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	3.61e-05	0.000201	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	3.6e-05	0.000201	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	3.58e-05	0.000199	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	3.51e-05	0.000196	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	3.51e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	3.5e-05	0.000195	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	3.49e-05	0.000194	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.48e-05	0.000194	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	3.47e-05	0.000193	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	3.44e-05	0.000192	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	3.4e-05	0.00019	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	3.37e-05	0.000188	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	3.34e-05	0.000186	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	3.27e-05	0.000183	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	3.26e-05	0.000182	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	3.23e-05	0.00018	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	3.18e-05	0.000177	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PTEN—pancreatic cancer	3.16e-05	0.000176	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	3.16e-05	0.000176	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	3.15e-05	0.000176	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	3.12e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	3.11e-05	0.000173	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	3.06e-05	0.000171	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	3.02e-05	0.000168	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	2.94e-05	0.000164	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	2.94e-05	0.000164	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	2.92e-05	0.000163	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	2.91e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	2.9e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	2.9e-05	0.000162	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	2.89e-05	0.000161	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.84e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	2.83e-05	0.000158	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	2.81e-05	0.000157	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	2.75e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	2.74e-05	0.000153	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.71e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	2.71e-05	0.000151	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	2.7e-05	0.00015	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	2.68e-05	0.000149	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	2.66e-05	0.000148	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	2.65e-05	0.000148	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	2.64e-05	0.000147	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	2.58e-05	0.000144	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	2.5e-05	0.000139	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	2.46e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	2.45e-05	0.000137	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	2.39e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	2.38e-05	0.000133	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	2.36e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	2.36e-05	0.000132	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	2.3e-05	0.000128	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	2.27e-05	0.000127	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—AKT1—pancreatic cancer	2.24e-05	0.000125	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	2.23e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	2.22e-05	0.000124	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	2.2e-05	0.000123	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	2.19e-05	0.000122	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	2.15e-05	0.00012	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	2.12e-05	0.000118	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	2.03e-05	0.000113	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	2.01e-05	0.000112	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	1.88e-05	0.000105	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.87e-05	0.000104	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.82e-05	0.000102	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.8e-05	0.000101	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.73e-05	9.62e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.52e-05	8.5e-05	CbGpPWpGaD
